Ikena Oncology Inc represents a commitment to advancing targeted cancer therapies. The company focuses on developing novel drugs that target specific pathways implicated in cancer growth and progression. With a mission to improve outcomes for patients, Ikena Oncology Inc prioritizes scientific excellence, innovation, and collaboration. By leveraging deep cancer biology expertise, the company aims to identify and develop potential breakthrough therapies. Ikena Oncology Inc believes in delivering on its commitments to patients, investors, and partners through integrity, transparency, and rigorous research. This company is dedicated to making a meaningful impact in the fight against cancer through its innovative approach and strong corporate values.

Ikena Oncology Inc is primarily present in the United States of America (USA).

Ikena Oncology Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in April 2021, raising approximately $100 million. In addition, Ikena Oncology Inc has demonstrated promising progress in its drug development programs, particularly in the field of targeted oncology therapeutics. The company has advanced its lead drug candidate, IK-007, into Phase 1 clinical trials, aiming to evaluate its safety and potential efficacy in patients with solid tumors. These milestones highlight Ikena Oncology Inc's commitment to advancing innovative therapies in the fight against cancer.

Ikena Oncology Inc is a pharmaceutical company specializing in the development of targeted oncology therapies. Founded in 2016, Ikena Oncology is dedicated to discovering and advancing novel treatments for cancer patients. With a focus on precision medicine, the company utilizes its deep expertise in molecular oncology to identify and target key pathways driving the growth and progression of various types of cancer. Through strategic collaborations and cutting-edge research, Ikena Oncology aims to revolutionize cancer care and improve patient outcomes. This commitment to innovation and patient-centric solutions has established Ikena Oncology as a leading player in the field of oncology therapeutics.

The main competitors of Ikena Oncology Inc in the market include other pharmaceutical and biotechnology companies focusing on oncology research and development. Some prominent competitors in this space include giants like Bristol-Myers Squibb, Merck & Co., Inc., and Pfizer Inc. These companies also aim to develop innovative treatments for various types of cancer. However, Ikena Oncology Inc distinguishes itself by leveraging its deep expertise in targeted cancer therapies and precision medicine, enabling the development of novel therapeutic options to address unmet medical needs.

Ikena Oncology Inc is primarily active in the biotechnology industry.

Ikena Oncology Inc's business model focuses on the development and commercialization of innovative targeted oncology therapies. The company aims to identify and develop novel cancer treatments by targeting key signaling pathways and genetic alterations in tumor cells. With a strong pipeline and strategic partnerships, Ikena Oncology is dedicated to advancing its therapies through preclinical and clinical studies to address the unmet needs of cancer patients. As a leading biotechnology company, Ikena Oncology Inc strives to deliver breakthrough treatments and improve patient outcomes in the field of oncology.

Ikena Oncology hissesinin F/K oranı -1,17.

Ikena Oncology KUV 0 dir.

Ikena Oncology için AlleAktien Kalite Skoru 2/10'dur.

Ikena Oncology için şu an ciro hesaplanamıyor.

beklenen Ikena Oncology karı -60,92 Milyon. USD olarak gerçekleşmiştir.

Ikena Oncology Inc. is a biopharmaceutical company focused on the development of cancer treatments. The company's main focus is on researching new compounds for common tumor types such as breast, lung, and kidney cancer, as well as rarer forms of the disease. Ikena Oncology's business model is based on identifying and developing potentially effective cancer drugs using cutting-edge technologies and research methods. The company utilizes a wide range of scientific tools and techniques to identify and validate target molecules in oncology. Ikena Oncology has a well-established pipeline of drug candidates in various stages of clinical development. The company has built an extensive collection of proprietary libraries of molecular compounds that serve as a starting point for the discovery of potential cancer drugs. The product portfolio of Ikena Oncology includes a range of drug candidates in various stages of development. This includes not only various small molecule inhibitors but also its own pipeline of immuno-oncology products designed to stimulate the immune system's response to cancer cells. The company pursues a broad strategy to expand and advance its product portfolio. This includes close collaboration with other stakeholders in cancer research, especially in the field of clinical trials. Ikena Oncology sees itself as a key partner for the pharmaceutical and biotech industry. With its focus on developing new cancer drugs, the company has made a name for itself in the biotech industry. Ikena Oncology places great emphasis on innovative approaches and advanced research methods. Through the use of state-of-the-art technologies and a strategic partnership approach, the company aims to strengthen its position and achieve its goals. Overall, Ikena Oncology's business model is geared towards developing and establishing new and effective drugs for the treatment of cancer. The company invests heavily in research and development and relies on close collaboration with other stakeholders in the scientific and biotech industry. The goal is to expand on previous successes and continue developing innovative solutions for fighting cancer.

Ikena Oncology, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Ikena Oncology için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Ikena Oncology şirketinin ISIN kodu US45175G1085’dir.

Ikena Oncology için Ticker IKNA’dir.

Son 12 ay içerisinde Ikena Oncology, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Ikena Oncology, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Ikena Oncology şirketinin mevcut temettü verimi .

Ikena Oncology dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Ikena Oncology, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Ikena Oncology, '—' sektörüne atanmıştır.

Son Ikena Oncology tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 01.11.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 01.11.2024 olarak gerçekleşti.

2023 yılında Ikena Oncology tarafından 0 USD olarak temettüler dağıtıldı.

Ikena Oncology hisselerinin temettüleri USD olarak dağıtılır.